Janus Henderson Group PLC An2 Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.93 - $3.76 $181 - $353	-94 Reduced 0.01%	1,221,051 $2.63 Million
Q1 2024 May 15, 2024	SELL	$2.78 - $21.53 $163,547 - $1.27 Million	-58,830 Reduced 4.6%	1,221,145 $3.97 Million
Q4 2023 Feb 14, 2024	SELL	$13.92 - $21.0 $1.52 Million - $2.29 Million	-108,975 Reduced 7.85%	1,279,975 $26.2 Million
Q3 2023 Nov 14, 2023	BUY	$7.58 - $16.08 $2.95 Million - $6.25 Million	388,882 Added 38.89%	1,388,950 $22.3 Million
Q2 2023 Aug 14, 2023	BUY	$5.06 - $9.91 $5.06 Million - $9.91 Million	1,000,068 New	1,000,068 $8.5 Million

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $26M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.